FORM PTO-1390 (Modified) (R2V 10-95)

U.S. DEPARTME

O THE UNITED STATES TRANSMITTAL LETTE DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATIONNO. (IF KNOWN, SEE 37 CFR 09/423018

NTERNATIONAL APPLICATIONNO.			INTERNATIONALFILING DATE	PRIORITY DATE CLAIMED	
PCT/US98/07587			16 April 1998	18 April 1997	
TTLE Type	OF IN	VENTION GF-Beta Receptor/Immuno	globulin Constant Region Fusion Pr	roteins	
	CANT	c(s) FOR DO/EO/US		•	
Applio	cant h	erewith submits to the United St	ates Designated/Elected Office (DO/EO/I	US) the following items and other information:	
1	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3.		This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4.		A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.			
5.	X	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))			
	a. is transmitted herewith (required only if not transmitted by the International Bureau).				
b. has been transmitted by the International Bureau.				i	
	c. \(\sum \) is not required, as the application was filed in the United States Receiving Office (RO/US).				
6.		A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7.		A copy of the International Search Report (PCT/ISA/210).			
8.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))			
i i		a. are transmitted herewith (required only if not transmitted by the International Bureau).			
į		b. have been transmitted by the International Bureau.			
4 Principal	c. have not been made; however, the time limit for making such amendments has NOT expired.				
	d. have not been made and will not be made.				
<u>.</u> 9.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9. 10.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).			
<u>.</u> 11.		A copy of the International Preliminary Examination Report (PCT/IPEA/409).			
]12.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).			
në It	tems 1	13 to 18 below concern docume	ent(s) or information included:		
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
15.		A FIRST preliminary amendment.			
		A SECOND or SUBSEQUEN			
16.		A substitute specification.			
17.		A change of power of attorney and/or address letter.			
18.	\boxtimes	Certificate of Mailing by Express Mail			
19.		Other items or information:			
			•		

420 Rec'd PCT/PTO 28 ATTORNEY'S DOCKET NUMBER INTERNATIONAL APPLICATION NO. S. APPLICATIONNO (IF KNOWN SEE 3 A018 PCT/US98/07587 CALCULATIONS PTO USE ONLY The following fees are submitted:. BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): \$930.00 Search Report has been prepared by the EPO or JPO International preliminary examination fee paid to USPTO (37 CFR 1.482) \$720.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$790.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO \$1,070.00 ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$98.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$930.00 □ 30 \square 20 Surcharge of \$130.00 for furnishing the oath or declaration later than \$0.00 months from the earliest claimed priority date (37 CFR 1.492 (e)). RATE 8 **NUMBER EXTRA** NUMBER FILED **CLAIMS** \$22.00 \$22.00 X - 20 = Total claims \$82.00 \$410.00 5 - 3= 8 Independent claims \$0.00 Multiple Dependent Claims (check if applicable). \$1,362.00 TOTAL OF ABOVE CALCULATIONS Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). \Box \$0.00 **SUBTOTAL** \$1,362.00 □ 30 Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). □ 20 \$0.00 TOTAL NATIONAL FEE \$1,362.00 = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). \$0.00 \$1,362.00 TOTAL FEES ENCLOSED = Amount to be: refunded \$ \$ charged to cover the above fees is enclosed. A check in the amount of to cover the above fees. in the amount of \$1,362.00 02-2327 Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment A duplicate copy of this sheet is enclosed. to Deposit Account No. 02-2327 NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: Warren A. Kaplan, SIGNATURE BIOGEN, INC. Warren A. Kaplan 14 Cambridge Center Cambridge, MA 02142 NAME (617) 679-3598 34,199 REGISTRATION NUMBER

DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE THE PATENT COOPERATION TREATY

In re application of:

Gotwals, et al.

International Serial No.:

PCT/US98/07587

Filing Date:

April 16, 1998

For:

12

Type II TGF-Beta Receptor/Immunoglobulin Constant Region

Fusion Proteins

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office as Express Label No. EL272416480US in an Express Mail Envelope addressed to BOX PCT, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: Ochber 28, 1999 Signature:

Transmittal Letter

Enclosed please find a Petition for Revival of An International Application For Patent Designating the U.S. Abandoned Unintentionally Under 37 CFR 1.137(b), Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. 371, and a copy of the published PCT application under Express Mail Label Number EL272416476US.

The Commissioner is hereby authorized to charge our deposit account No. 02-2327 to cover the above fees including fees for Petition and National filing including excess claims. The Commissioner is hereby authorized to charge any additional fees, which may be required, or credit any overpayment to Deposit Account No. 02-2327.

Respectfully submitted,

Want/w Warren A. Kaplan

Reg. No. 34,199 BIOGEN, INC.

14 Cambridge Center

Cambridge, MA 02142

(617) 679-3598